IMC Chicago’s Iovance Biotherapeutics IOVA Stock Holding History

IMC Chicago’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$6.01M	Buy	+405,300	New	+$2.9M	﹤0.01%	2066

Other funds holding IOVA

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Jupiter Asset Management London, United Kingdom $21.4B AUM 19.74% 1-Year Est. Return

IMC Chicago's IOVA Position: Q3 2026 in Review

IMC Chicago increased its Iovance Biotherapeutics (IOVA) stake by 710% in Q3 2026, buying an estimated $671K and bringing the position to 106,922 shares worth $1.58M. The position accounts for ﹤0.01% of the portfolio, ranked #3380.

IMC Chicago first reported a position in IOVA in Q2 2026 and has held it in 2 quarters since. 253 funds tracked by Wall St. Rank hold IOVA as of Q3 2026.

IMC Chicago held 106,922 shares of Iovance Biotherapeutics worth $1.58M as of Q3 2026.
IMC Chicago bought 93,722 Iovance Biotherapeutics shares in Q3 2026, an estimated $671K.
Iovance Biotherapeutics made up ﹤0.01% of IMC Chicago's portfolio in Q3 2026, its #3380 holding.
IMC Chicago first reported a position in Iovance Biotherapeutics in Q2 2026 and has held it in 2 quarters since.
253 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2026.

Based on IMC Chicago's 13F filing for Q3 2026, filed 5 Nov 2026.